NextMed
NextMed operates the largest US mobile lithotripsy platform, providing AI-enhanced ESWL kidney stone treatment services, trained technologists, and decision-support tools to more than 1,000 urologists and 400 medical facilities nationwide, with sub-brands NextWave (in-office treatment) and URS+ (ureteroscopy services).
- Company typePrivate
- Founded1996
- HeadquartersTucson, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What NextMed does
NextMed, LLC is a privately held, founder-owned urology services company founded in 1996 in Tucson, Arizona, that operates the largest US mobile lithotripsy platform serving more than 400 medical facilities and 1,000 urologists nationwide. Its core business is providing mobile Extracorporeal Shock Wave Lithotripsy (ESWL) units, trained technologists, and data-driven treatment protocols to physician offices and hospitals, enabling partners to offer non-invasive kidney stone treatment without owning equipment or maintaining specialized staff. The company extends this platform through NextWave (in-office ESWL delivered inside the urologist's own office), URS+ (ureteroscopy services including capital equipment, consumables, and technicians), and the AI Smart Litho technology suite, which encompasses the Stone Decision Engine (a predictive treatment recommendation algorithm), the International Stone Registry (a proprietary outcomes database of 200,000+ patients and 1,000+ urologists), the Hamilton, Gerber ESWL Training Simulator, and TAS Analytics for technologist performance monitoring.
NextMed generates revenue primarily through managed-service partnerships with physicians and facilities, with custom negotiated, multi-year contracts and a parallel direct-to-consumer channel via the Physician Finder tool. The company supplements its service revenue with a physician-partnership investment model in which urologists take equity positions; one disclosed example cites a $50,000 investment 15+ years ago generating a seven-figure return. Go-to-market is sales-led, executed through business developers who engage urologists and facilities directly, supported by a website, social media, patient education content, and product-led growth through the Stone Decision Engine app. The company holds the only HFAP Comprehensive Lithotripsy Program certification in the United States and the only ACHC comprehensive lithotripsy certification among urology service providers, both of which it helped develop alongside The Joint Commission, and self-reports industry-leading outcomes including an 86.3% ESWL success rate, 4.5% complication rate (vs. 8.4% industry standard), and over 99% patient success rate.
The business is bootstrapped and founder-operated by the Gleason family with no disclosed institutional investors, parent company, or material external funding (a single $170K raise in April 2022 is the only capital event on record). It has continuously operated for 24+ years and is structured as an Arizona LLC headquartered at 6339 E Speedway Blvd, Tucson. Headcount sits in the 101–250 range, and the company's website displays a 2020 copyright notice, indicating source material was captured around that period, which constrains visibility into more recent developments.
NextMed firmographics
Firmographics- Name
- NextMed
- Legal name
- NextMed, LLC
- Website
- https://nextmed.net
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- NextMed operates the largest US mobile lithotripsy platform, providing AI-enhanced ESWL kidney stone treatment services, trained technologists, and decision-support tools to more than 1,000 urologists and 400 medical facilities nationwide, with sub-brands NextWave (in-office treatment) and URS+ (ureteroscopy services).
- Ownership category
- akta.pro rank
NextMed industry classification
Industry- Product category
- Urology Services
- NAICS
- Ambulatory Health Care Services (621)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000)
- akta.pro primary industry
- Kidney Stone Management & Lithotripsy Devices (HLAHAKAI)
- akta.pro secondary industries
- Diagnostic & Triage Decision Support (HLACAGAA), Endourology & Minimally Invasive Urologic Surgery (HLAKAOAF)
Keywords
Where NextMed is headquartered
LocationHeadquarters
- HQ city
- Tucson
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NextMed business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Lithotripsy Services: NextMed provides mobile lithotripsy services to urologists and medical facilities. The company operates mobile lithotripsy units that travel to partner facilities, providing non-invasive kidney stone treatment (ESWL). Physicians and facilities partner with NextMed to access state-of-the-art lithotripsy technology, highly trained technologists, and data-driven treatment protocols. The company was founded on principles of transparent financial operations.
- NextWave In-Office Treatment Services: NextWave brings kidney stone treatment directly to physician offices, providing in-office ESWL treatment with a focused treatment team. This service generates revenue by enabling physicians to perform lithotripsy in their own facilities with NextMed's equipment, technology, and technologist support.
- Physician Partnership Investments: Physicians invest in NextMed partnerships, with testimonials indicating significant returns. One physician noted a $50,000 total investment 15+ years ago netting a seven-figure return. This suggests a model where physicians become equity partners or investors in the lithotripsy business.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom partnership pricing based on physician and facility needs |
| Other | Multi-year contract | Quote-based pricing for lithotripsy services |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
NextMed product offering
Product offeringCore offering
NextMed provides mobile Extracorporeal Shock Wave Lithotripsy (ESWL) services to urologists and medical facilities across the United States, bringing lithotripsy equipment, AI-powered treatment protocols, and trained technologists directly to partner sites. The company also offers the NextWave in-office treatment service for physicians and the URS+ ureteroscopy program, all supported by the proprietary AI Smart Litho technology platform including the Stone Decision Engine and International Stone Registry.
Product overview
NextMed operates as a comprehensive urology services company offering a platform of lithotripsy and urological treatment services. The core offering consists of mobile lithotripsy services using ESWL technology, supplemented by the NextWave in-office treatment sub-brand and the URS+ ureteroscopy service. Central to their differentiation is the AI Smart Litho technology platform, which includes the Stone Decision Engine (predictive treatment recommendation tool), International Stone Registry (clinical outcomes database), and Hamilton, Gerber Training Simulator (physician training tool). NextMed delivers treatment through partnered physicians and facilities nationwide, serving over 400 facilities and 1,000 physicians with demonstrated outcomes including 99% patient success rate and 86.3% ESWL treatment success rate.
Differentiator
Problem solved
Functional benefit
Brands
- NextWave: In-office kidney stone treatment service bringing ESWL treatment directly to physician offices, providing convenient in-office treatment options for patients.
- URS+
- AI Smart Litho
Products and services
- Mobile Lithotripsy Service NextMed's core mobile lithotripsy service that deploys ESWL equipment and trained technologists to partner urology practices, hospitals, and medical facilities across the United States. Provides non-invasive kidney stone treatment on-site without requiring facilities to invest in lithotripsy equipment.
- NextWave In-Office Treatment Sub-brand service that brings ESWL kidney stone treatment to the physician's office, allowing patients to receive treatment in their urologist's office rather than a hospital. Includes NextMed equipment, technologists, and focused treatment team support.
- URS+ Ureteroscopy Service Comprehensive ureteroscopy service for urologists and medical facilities providing capital equipment, full suite of consumables, expert technicians, and flexible care settings to address labor shortages and capital equipment needs.
- AI Smart Litho Technology Platform NextMed's proprietary AI technology platform integrating predictive algorithms, the Stone Decision Engine, the International Stone Registry, and the ESWL Training Simulator to optimize kidney stone treatment selection and delivery.
- Stone Decision Engine (SDE) Standalone predictive tool for patients and physicians that determines the best kidney stone treatment options and predicts success and complication rates based on stone characteristics, patient demographics, and anesthesia preferences.
- International Stone Registry (ISR) Clinical outcomes registry aggregating treatment and outcomes data from over 200,000 patients and 1,000 treating urologists, powered by cloud computing and advanced analytical tools to support treatment decisions.
- Hamilton, Gerber ESWL Training Simulator ESWL training simulator for physicians that uses scientific data and patient-specific information to teach optimal shock protocol delivery for Extracorporeal Shock Wave Lithotripsy procedures.
Quantifiable outcome
- 86.3% ESWL Treatment Success Rate in the last year with Stone Free Rate of 66.3%
- +9 more outcomes
Companies that use NextMed
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
NextMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
NextMed partnerships and signals
Strategic signalScale indicators20 records
Recent moves6 records
Expansion highlights6 records
NextMed competitors and assessment
Company assessmentBroad incumbents
- Karl Storz: Global leader in endoscopy and urology visualization systems. Karl Storz is a broad incumbent in urology whose ureteroscopy and endoscopy equipment overlaps with NextMed's URS+ ureteroscopy service line and broader urology practice economics.
- Medtronic: Diversified medical device giant with a meaningful urology business (acquired through Covidien and other deals). Medtronic competes broadly in urology and is a potential alternative vendor for hospitals weighing mobile lithotripsy outsourcing versus in-house capital investment.
- Cook Medical: Privately held medical device manufacturer with a substantial urology portfolio including ureteral stents, stone baskets, and ureteroscopy accessories. Cook Medical overlaps with NextMed's URS+ ureteroscopy consumables offering and broader urology supply chain.
- Hologic: Diversified women's health and surgical company with adjacent urology and surgical service exposure. Hologic is a broad incumbent whose hospital relationships and surgical service infrastructure overlap with NextMed's facility-partnership go-to-market.
- Teleflex: Medical technology company with a urology portfolio including ureteral access sheaths, stone baskets, and stents. Teleflex is an incumbent supplier whose products overlap with NextMed's URS+ consumables offering and broader urology procedure economics.
- Boston Scientific: Large diversified medical device company with a significant urology franchise (including lithotripsy, ureteroscopy, and stone management products). Boston Scientific competes across multiple of NextMed's service lines as a broader incumbent.
- Richard Wolf: German medical technology company specializing in urology, endoscopy, and lithotripsy solutions. Richard Wolf is a broad incumbent whose equipment and consumables portfolio competes across NextMed's mobile lithotripsy and ureteroscopy service lines.
- Olympus: Global leader in endoscopy with strong urology exposure including flexible ureteroscopes and stone management devices. Olympus competes as an incumbent equipment vendor for hospitals and ASCs evaluating lithotripsy and ureteroscopy capabilities.
Direct peers
- Storz Medical: Swiss manufacturer of shock wave lithotripsy and focused ultrasound devices. Storz Medical supplies ESWL equipment that competes with NextMed's mobile lithotripsy service offering and is a likely technology partner or competitor for any hospital considering insourcing.
- Dornier MedTech: A leading global manufacturer of lithotripsy devices and ESWL systems. Dornier competes directly with NextMed in the kidney stone management equipment market that NextMed services, particularly for hospitals evaluating whether to outsource mobile lithotripsy or purchase equipment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
NextMed social profiles
Digital presenceNextMed compliance and trust
Trust signalCompliance3 records
NextMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
NextMed leadership team
Management profileNumber of profiles
Profiles2 records
NextMed funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NextMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NextMed
What does NextMed do?
NextMed provides mobile Extracorporeal Shock Wave Lithotripsy (ESWL) services to urologists and medical facilities across the United States, bringing lithotripsy equipment, AI-powered treatment protocols, and trained technologists directly to partner sites. The company also offers the NextWave in-office treatment service for physicians and the URS+ ureteroscopy program, all supported by the proprietary AI Smart Litho technology platform including the Stone Decision Engine and International Stone Registry.
Is NextMed a public or private company?
NextMed is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NextMed founded?
NextMed was founded in 1996. It employs 101 to 250 people.
Where is NextMed based?
NextMed is headquartered in Tucson, United States, in the North America region.
How does NextMed make money?
Three revenue lines are on record. Lithotripsy Services are the primary driver. The others are nextWave In-Office Treatment Services and physician Partnership Investments.
Who are NextMed's main competitors?
Broad incumbents on record are Karl Storz, Medtronic, Cook Medical, Hologic, Teleflex, Boston Scientific, Richard Wolf and Olympus. Direct peers are Storz Medical and Dornier MedTech.
Does NextMed have an API?
No public API is recorded for NextMed.
What industry is NextMed in?
NextMed's product category is Urology Services. Its primary akta.pro industry code is HLAHAKAI, Kidney Stone Management & Lithotripsy Devices, with a secondary code of HLACAGAA, Diagnostic & Triage Decision Support. Its NAICS code is 621 and its SIC code is 3845.